Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
Trial record 1 of 1 for:    NCT03529773
Previous Study | Return to List | Next Study

A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03529773
Recruitment Status : Active, not recruiting
First Posted : May 18, 2018
Last Update Posted : October 2, 2019
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:
The study will describe the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations when administered alone or concomitantly with seasonal inactivated influenza vaccine (SIIV).

Condition or disease Intervention/treatment Phase
Respiratory Tract Infections Biological: Formulation A Biological: Formulation B Biological: Placebo Phase 2

Detailed Description:
The study will describe the safety, tolerability, and immunogenicity of up to 6 RSV vaccine formulations when administered alone or concomitantly with SIIV. Healthy male and female subjects divided into 2 age groups (18-49 years of age and 50-85 years of age in the sentinel cohort and 18-49 years of age and 65-85 years of age in the expanded cohort) will be enrolled. Age groups will run in parallel. Subjects in the sentinel cohort in each age group will receive one of two RSV vaccine formulations at one of 3 antigen dose levels or placebo. Subjects in the expanded cohort in each age group will receive one of two RSV vaccine formulations at one of 3 antigen dose levels with and without SIIV.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 1235 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Observer blind
Primary Purpose: Prevention
Official Title: A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY ADULTS
Actual Study Start Date : April 18, 2018
Estimated Primary Completion Date : November 1, 2019
Estimated Study Completion Date : December 25, 2020

Arm Intervention/treatment
Experimental: Sentinel Arm 1
Low dose formulation A
Biological: Formulation A
RSV vaccine

Experimental: Sentinel Arm 2
Mid dose formulation A
Biological: Formulation A
RSV vaccine

Experimental: Sentinel Arm 3
High dose formulation A
Biological: Formulation A
RSV vaccine

Experimental: Sentinel Arm 4
Low dose formulation B
Biological: Formulation B
RSV vaccine

Experimental: Sentinel Arm 5
Mid dose formulation B
Biological: Formulation B
RSV vaccine

Experimental: Sentinel Arm 6
High dose formulation B
Biological: Formulation B
RSV vaccine

Placebo Comparator: Sentinel Arm 7
Placebo
Biological: Placebo
Placebo

Experimental: Expanded Arm 8
Low dose formulation A and SIIV
Biological: Formulation A
RSV vaccine

Experimental: Expanded Arm 9
Mid dose formulation A and SIIV
Biological: Formulation A
RSV vaccine

Experimental: Expanded Arm 10
High dose formulation A and SIIV
Biological: Formulation A
RSV vaccine

Experimental: Expanded Arm 11
Low dose formulation B and SIIV
Biological: Formulation B
RSV vaccine

Experimental: Expanded Arm 12
Mid dose formulation B and SIIV
Biological: Formulation B
RSV vaccine

Experimental: Expanded Arm 13
High dose formulation B and SIIV
Biological: Formulation B
RSV vaccine

Experimental: Expanded Arm 14
Low dose formulation A and placebo
Biological: Formulation A
RSV vaccine

Experimental: Expanded Arm 15
Mid dose formulation A and placebo
Biological: Formulation A
RSV vaccine

Experimental: Expanded Arm 16
High dose formulation A and placebo
Biological: Formulation A
RSV vaccine

Experimental: Expanded Arm 17
Low dose formulation B and placebo
Biological: Formulation B
RSV vaccine

Experimental: Expanded Arm 18
Mid dose formulation B and placebo
Biological: Formulation B
RSV vaccine

Experimental: Expanded Arm 19
High dose formulation B and placebo
Biological: Formulation B
RSV vaccine

Placebo Comparator: Expanded Arm 20
placebo and placebo
Biological: Placebo
Placebo




Primary Outcome Measures :
  1. Percentage of subjects reporting local reactions and systemic events from day of vaccination 1 until Day 14 [ Time Frame: From day of vaccination 1 until Day 14 ]
    Describe local reactions and systemic events after 1 dose of investigational product

  2. Percentage of subjects reporting Adverse Events (AEs) within 1 month after vaccination 1 [ Time Frame: Within 1 month after vaccination 1 ]
    Describe adverse events (AEs) after 1 dose of investigational product

  3. Percentage of subjects with at least 1 medically attended adverse event (MAE) or serious adverse events (SAE) within 30 days after each vaccination, or during the follow-up phase [ Time Frame: Up to 12 months ]
    Describe medically attended (MAEs) and serious adverse events (SAEs)

  4. Percentage of subjects reporting adverse evnts (AEs) within 1 month after vaccination 2 [ Time Frame: Within 1 month after vaccination 2 ]
    Describe adverse events (AEs) after vaccination 2


Secondary Outcome Measures :
  1. RSV A- and RSV B-neutralizing antibody titers [ Time Frame: RSV A- and RSV B-neutralizing antibody titers measured at baseline, 2 weeks (sentinel subjects only) and 1, 2, 3, and 6 months after vaccination 1. ]
    Immune responses measured by RSV A- and RSV B-neutralizing antibody titers at specified timepoints.

  2. Hemagglutination inhibition assay (HAI) titers [ Time Frame: At baseline and 1 month after SIIV administration ]
    Immune responses as measured by HAI titers at specified timepoints.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Evidence of a personally signed and dated informed consent document (ICD) indicating that the subject has been informed of all pertinent aspects of the study.
  2. Healthy adults who are determined by medical history, physical examination, and clinical judgment of the investigator to be eligible for inclusion in the study.
  3. Willing and able to comply with scheduled visits, vaccination plan, laboratory tests, and other study procedures.
  4. Male subject who is able to father children and willing to use a highly effective method of contraception as outlined in this protocol until at least 28 days after the last dose of investigational product; female subject who is of childbearing potential and at risk for pregnancy and who is willing to use a highly effective method of contraception as outlined in this protocol until at least 28 days after the last dose of investigational product; male subject not able to father children; female subject not of childbearing potential.
  5. Sentinel-cohort subjects only: Male and female adults aged 18 to 85 years at the time of enrollment (signing of the ICD).
  6. Expanded-cohort subjects only: Male and female adults aged 18 to 49 years of age or 65 to 85 years at the time of enrollment (signing of the ICD).

Exclusion Criteria:

  1. Sentinel-cohort subjects only: Any screening hematology and/or blood chemistry laboratory value that meets the definition of a ≥ Grade 1 abnormality.
  2. Sentinel-cohort subjects only: Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (HBc Abs), or hepatitis C virus antibodies (HCV Abs) at the screening visit.
  3. Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
  4. Participation in other studies involving investigational product within 28 days prior to study entry and/or during study participation.
  5. Known infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).
  6. Previous vaccination with any licensed or investigational RSV vaccine, or planned receipt throughout the study of nonstudy RSV vaccine.
  7. History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the investigational product(s).
  8. Immunocompromised subjects with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  9. Subjects who receive treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, subjects should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before investigational product administration. Intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  10. Subject with a history of autoimmune disease or an active autoimmune disease requiring therapeutic intervention including but not limited to: systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin-dependent diabetes mellitus (type 1).
  11. Receipt of blood/plasma products or immunoglobulin, from 60 days before investigational product administration or planned receipt throughout the study.
  12. Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
  13. Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  14. Women who are pregnant or breastfeeding.
  15. Expanded-cohort subjects only: Vaccination with any influenza vaccine within 6 months (182 days) before investigational product administration.
  16. Expanded-cohort subjects only: Allergy to egg proteins (egg or egg products) or chicken proteins.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03529773


Locations
Show Show 41 study locations
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT03529773    
Other Study ID Numbers: C3671001
RSV FIH ( Other Identifier: Alias Study Number )
First Posted: May 18, 2018    Key Record Dates
Last Update Posted: October 2, 2019
Last Verified: October 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Time Frame: Starting 24 months after study completion.
URL: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
Respiratory tract infections, RSV, vaccine
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Infection
Respiratory Tract Diseases
Vaccines
Immunologic Factors
Physiological Effects of Drugs